Wang Yunliang, Liu Lijuan, Guo Yi, Mao Tangyou, Shi Rui, Li Junxiang
Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China.
Gastroenterology Department of Traditional Chinese Medicine, China-Japan Friendship Hospital, Beijing 100029, P.R. China.
Exp Ther Med. 2017 Aug;14(2):1327-1336. doi: 10.3892/etm.2017.4701. Epub 2017 Jun 28.
The effects of indigo naturalis (IN), which is a traditional Chinese herbal formulation, have been clinically demonstrated in treating refractory ulcerative colitis (UC). The present study aimed to verify the effects and mechanisms of IN in experimental UC rats. A total of 48 male Sprague-Dawley rats were randomly divided into six groups: Chow, model, high-dose IN, medium-dose IN, low-dose IN and mesalazine (a bowel-specific aminosalicylate drug) groups. The models were administered 3.5% dextran sodium sulphate solution for 7 days. The treatment groups were administered IN or mesalazine and then sacrificed and sampled on day 8. Disease activity index (DAI), histological damage score (HDS) and myeloperoxidase (MPO) activity were used to evaluate the severity of UC. Colon and serum cytokines were detected using liquid-phase chip technology and the expression of occludin protein in colonic mucosa was assessed by immunohistochemistry and western blot analysis. The results indicated that the oral administration of IN may reduce DAI, HDS and MPO activity. IN also reduced the expression of inflammatory cytokines and increased the expression of colonic mucosal repair-related cytokines and occludin protein. These results highlight the potential of IN as a therapeutic agent for treating UC through its action of inflammation control and colonic mucosal damage repair.
青黛(IN)是一种传统的中药制剂,其在治疗难治性溃疡性结肠炎(UC)方面的疗效已得到临床证实。本研究旨在验证青黛对实验性UC大鼠的作用及机制。将48只雄性Sprague-Dawley大鼠随机分为六组:正常饮食组、模型组、高剂量青黛组、中剂量青黛组、低剂量青黛组和美沙拉嗪(一种肠道特异性氨基水杨酸盐药物)组。给模型组大鼠给予3.5%葡聚糖硫酸钠溶液,持续7天。治疗组给予青黛或美沙拉嗪,然后在第8天处死并取样。采用疾病活动指数(DAI)、组织学损伤评分(HDS)和髓过氧化物酶(MPO)活性来评估UC的严重程度。使用液相芯片技术检测结肠和血清细胞因子,并通过免疫组织化学和蛋白质印迹分析评估结肠黏膜中闭合蛋白的表达。结果表明,口服青黛可降低DAI、HDS和MPO活性。青黛还可降低炎症细胞因子的表达,并增加结肠黏膜修复相关细胞因子和闭合蛋白的表达。这些结果凸显了青黛通过控制炎症和修复结肠黏膜损伤来治疗UC的潜在治疗作用。